Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$32.81 USD

32.81
2,780,141

+0.16 (0.49%)

Updated May 17, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 24% (189 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

What to Expect from Prothena (PRTA) This Earnings Season?

by Zacks Equity Research

Prothena Corporation plc (PRTA) is expected to report first-quarter 2017 results early next month.

    Novartis Tops Q1 Earnings: Cosentyx, Entresto Boost Sales

    by Zacks Equity Research

    Novartis AG (NVS) reported first-quarter 2017 core earnings of $1.13 per share, beating the Zacks Consensus Estimate of $1.10.

      Arpita Dutt headshot

      Pharma Stock Roundup: J&J Slips on Mixed Q1, Lilly Hit by FDA CRL

      by Arpita Dutt

      Key highlights from the pharma sector include J&J's (JNJ) first quarter results and a CRL for Lilly's RA drug.

        Ryan McQueeney headshot

        After Johnson & Johnson Earnings, Buy These Pharma Stocks

        by Ryan McQueeney

        Shares of Johnson & Johnson (JNJ) slid nearly 3.5% in morning trading Tuesday after the pharma giant's first-quarter earnings results were met with mixed reactions from investors. As the sell-off continues, investors focused on large-cap pharma companies may want to move their money into stronger options this earnings season.

          Roche's (RHHBY) Cancer Drug Gets FDA Nod for Label Expansion

          by Zacks Equity Research

          Roche Holding AG's (RHHBY) unit, Genentech, announced that its drug Tecentriq (atezolizumab) has received FDA approval on an accelerated basis for initial treatment of people with advanced urothelial carcinoma (mUC).

            Roche's Hemophilia A Drug Positive in Second Phase III Study

            by Zacks Equity Research

            Roche Holding AG's (RHHBY) unit, Genentech, announced positive interim results from the Phase III HAVEN 2 study evaluating its pipeline candidate emicizumab prophylaxis.

              Roche Launches Antibody Test to Diagnose Prostate Cancer

              by Zacks Equity Research

              Roche Holding AG (RHHBY) announced that it has launched the anti-p504s (SP116) Rabbit Monoclonal Primary Antibody for prostate cancer diagnosis on a world wise basis.

                Arpita Dutt headshot

                Pharma Stock Roundup: Merck Gets CRL for Label Expansion Effort, Roche Cancer Drug Tops

                by Arpita Dutt

                Key highlights this week include a complete response letter (CRL) for Merck (MRK) and some positive data from Roche.

                  Geron Stock Rises after Positive Interim Update on Imetelstat

                  by Zacks Equity Research

                  Shares of Geron Corporation (GERN) increased almost 20% on Monday after it provided a positive update on two late-stage studies for imetelstat, its lead pipeline candidate.

                    Louisiana-Pacific, Bed Bath & Beyond, Roche Holdings AG, Adidas AG and Deere highlighted as Zacks Bull and Bear of the Day

                    by Zacks Equity Research

                    Louisiana-Pacific, Bed Bath & Beyond, Roche Holdings AG, Adidas AG and Deere highlighted as Zacks Bull and Bear of the Day

                      Arpita Dutt headshot

                      Forget Novartis, Buy These Two Pharma Stocks Instead

                      by Arpita Dutt

                      With Novartis (NVS) being a Zacks Rank #4 (Sell) stock, here is a look at two European pharma stocks that sport a strong Zacks Rank.

                        Roche's Lung Cancer Drug Alecensa Meets Primary Endpoint

                        by Zacks Equity Research

                        Roche (RHHBY) announced that the global, randomized phase III study, ALEX, on lung cancer drug Alecensa met its primary endpoint as an initial (first-line) treatment.

                          John Blank headshot

                          Huh? Brazil Matters? Global Week Ahead

                          by John Blank

                          Peaking at +10.7% y/y in January 2016, Brazilian inflation now runs under +5% y/y. Risk markets in Brazil have also sharply pared down forward inflation expectations.

                            Allergan (AGN) Presents Mixed Depression Data on Botox

                            by Zacks Equity Research

                            Allergan plc (AGN) announced mixed top-line data from a mid-stage study evaluating its key drug Botox for the treatment of major depressive disorder (MDD).

                              Roche Announces Positive Data on Lung Cancer Drug Alecensa

                              by Zacks Equity Research

                              Roche Holdings AG (RHHBY) recently announced encouraging results from the phase III study, ALUR on lung cancer drug Alecensa.

                                AbbVie/J&J's Imbruvica Label Expansion Filing Accepted by FDA

                                by Zacks Equity Research

                                AbbVie Inc. (ABBV) and partner Janssen, Johnson & Johnson's (JNJ) pharmaceuticals subsidiary, announced that a supplemental new drug application (sNDA) for their cancer drug Imbruvica has been accepted for review by the FDA.

                                  Bristol-Myers Announces Data on Immuno-oncology Drug Opdivo

                                  by Zacks Equity Research

                                  Bristol-Myers Squibb Company (BMY) recently announced encouraging data from various trials on Opdivo.

                                    Sanofi's (SNY) Diabetes Drug Toujeo Lowers Hypoglycemia Risk

                                    by Zacks Equity Research

                                    A real-world observational study showed that when type 2 diabetes patients on basal insulin switched to Toujeo, it led to a significant reduction in risk of hypoglycemia without compromising blood sugar control

                                      Bristol-Myers (BMY), Incyte to Advance Clinical Program

                                      by Zacks Equity Research

                                      Bristol-Myers Squibb Company (BMY) and Incyte Corporation (INCY) recently announced that the companies will advance their clinical development program.

                                        AstraZeneca's (AZN) Lung Cancer Drug Gets Full FDA Approval

                                        by Zacks Equity Research

                                        AstraZeneca plc (AZN) announced that its lung cancer drug, Tagrisso has received full approval from the FDA.

                                          Pfizer Gets Regular Approval for Breast Cancer Drug Ibrance

                                          by Zacks Equity Research

                                          Pfizer, Inc. (PFE) announced that its supplemental new drug application (sNDA) to convert accelerated approval for Ibrance to regular approval has been approved by the FDA.

                                            Arpita Dutt headshot

                                            4 FDA Decisions to Watch Out for in Apr 2017

                                            by Arpita Dutt

                                            Companies like BioMarin (BMRN), Roche and Takeda among others have regulatory decisions scheduled for this month.

                                              Mylan Receives CRL for Generic Advair Diskus From the FDA

                                              by Zacks Equity Research

                                              Mylan N.V. (MYL) recently suffered a huge setback when it received a complete response letter from the FDA regarding its ANDA for the generic version of asthma drug Advair Diskus.

                                                AbbVie's (ABBV) Humira Drug Label Update Approved by FDA

                                                by Zacks Equity Research

                                                AbbVie Inc.'s (ABBV) announced that the FDA has approved the inclusion of moderate to severe fingernail psoriasis data on the label of AbbVie???s multi-utility TNF blocker drug, Humira

                                                  Arpita Dutt headshot

                                                  Pharma Stock Roundup: FDA Nod for SNY, Roche Drugs, Generic Advair Relief for GSK?

                                                  by Arpita Dutt

                                                  Two drugs with blockbuster potential - Sanofi (SNY)/Regeneron's Dupixent and Roche's Ocrevus - gained FDA approval this week.